Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
作者： Qiao Wang , Hongling Peng , Xiaorong Qi , Min Wu , Xia Zhao
DOI: 10.1038/S41392-020-0199-6
关键词: Immune checkpoint inhibitors 、 Effective treatment 、 Cancer research 、 Poor prognosis 、 Cancer 、 Poly ADP ribose polymerase 、 Signal transduction 、 Medicine 、 Clinical evidence 、 Estrogen receptor
摘要: … 15 mg/kg intravenously weekly) to single-agent weekly paclitaxel in recurrent OC … plus etoposide showed promising efficacy and manageable toxicities in patients with platinum-resistant …
nature.com
scilit.net参考文章(427)
Lucely Cetina, Tania Crombet, Roberto Jiménez-Lima, Sergio Zapata, Mayra Ramos, Sandra Avila, Jaime Coronel, Eduardo Charco, Rafael Bojalil, Horacio Astudillo, Blanca Bazán, Alfonso Dueñas-González, A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer Cancer Biology & Therapy. ,vol. 16, pp. 684- 689 ,(2015) , 10.1080/15384047.2015.1026483
Angelica Nogueira-Rodrigues, Giulliana Moralez, Rachele Grazziotin, Claudio C. Carmo, Isabele A. Small, Flavia V.G. Alves, Marcelo Mamede, Felipe Erlich, Celia Viegas, Sergio A. Triginelli, Carlos G. Ferreira, Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer Cancer. ,vol. 120, pp. 1187- 1193 ,(2014) , 10.1002/CNCR.28471
Akila N. Viswanathan, Jennifer Moughan, Brigitte E. Miller, Ying Xiao, Anuja Jhingran, Lorraine Portelance, Walter R. Bosch, Ursula A. Matulonis, Neil S. Horowitz, Robert S. Mannel, Luis Souhami, Beth A. Erickson, Kathryn A. Winter, William Small, David K. Gaffney, NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. ,vol. 121, pp. 2156- 2163 ,(2015) , 10.1002/CNCR.29337
Helen J. Mackay, Elizabeth A. Eisenhauer, Suzanne Kamel-Reid, Ming Tsao, Blaise Clarke, Katherine Karakasis, Henrica M. J. Werner, Jone Trovik, Lars A. Akslen, Helga B. Salvesen, Dongsheng Tu, Amit M. Oza, Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer Cancer. ,vol. 120, pp. 603- 610 ,(2014) , 10.1002/CNCR.28414
B Milojkovic Kerklaan, M P J Lolkema, L A Devriese, E E Voest, A Nol-Boekel, M Mergui-Roelvink, M Langenberg, K Mykulowycz, J Stoebenau, S Lane, P Legenne, P Wissel, D A Smith, B J Giantonio, J H M Schellens, P O Witteveen, Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours British Journal of Cancer. ,vol. 113, pp. 706- 715 ,(2015) , 10.1038/BJC.2015.257
Carol Aghajanian, Barbara Goff, Lawrence R. Nycum, Yan V. Wang, Amreen Husain, Stephanie V. Blank, Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. ,vol. 139, pp. 10- 16 ,(2015) , 10.1016/J.YGYNO.2015.08.004
Sahra Borgés, Elara Moudilou, Cécile Vouyovitch, Jean Chiesa, Peter Lobie, Hichem Mertani, Mireille Raccurt, None, Involvement of a JAK/STAT Pathway Inhibitor: Cytokine Inducible SH2 Containing Protein in Breast Cancer Hormonal Carcinogenesis V. ,vol. 617, pp. 321- 329 ,(2008) , 10.1007/978-0-387-69080-3_30
Mark S Duxbury, Hiromichi Ito, Michael J Zinner, Stanley W Ashley, Edward E Whang, siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity1 1No competing interests declared.This work was funded by the National Pancreas Foundation and departmental funding, Brigham and Women’s Hospital. Journal of the American College of Surgeons. ,vol. 198, pp. 953- 959 ,(2004) , 10.1016/J.JAMCOLLSURG.2004.01.037
Whitney Graybill, Anil K. Sood, Bradley J. Monk, Robert L. Coleman, State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic Oncology. ,vol. 138, pp. 223- 226 ,(2015) , 10.1016/J.YGYNO.2015.07.008
N. Colombo, S. McMeekin, P. Schwartz, J. Kostka, C. Sessa, P. Gehrig, R. Holloway, P. Braly, D. Matei, M. Einstein, A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer Journal of Clinical Oncology. ,vol. 25, pp. 5516- 5516 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.5516